{"GBM":[{"dataset":"PRJEB23709","Description":"GBM-PRJEB23709-Gide Cancer cell, 2019. PMID:30753825.(91) ","PMID":"30753825","reference":"Zhao J, Chen A X, Gartrell R D, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma[J]. Nature medicine, 2019, 25(3): 462."}],
"SKCM":[{"dataset":"SRP094781","Description":"SKCM-SRP094781-Riaz Cell, 2017. PMID:29033130.(109)","PMID":"29033130","reference":"Riaz N, Havel J J, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab[J]. Cell, 2017, 171(4): 934-949. e16."},
	{"dataset":"PRJEB23709","Description":"SKCM-PRJEB23709-Gide Cancer cell, 2019.PMID:30753825.(91)","PMID":"30753825","reference":"Gide T N, Quek C, Menzies A M, et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy[J]. Cancer cell, 2019, 35(2): 238-255. e6."},
	{"dataset":"phs000452","Description":"SKCM-phs000452-Van Science, 2015. PMID:26359337.(42)","PMID":"26359337","reference":"Auslander N, Zhang G, Lee J S, et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma[J]. Nature medicine, 2018, 24(10): 1545."}]}